TEST:

Galen™ Prostate

The subsequent AI integration into routine clinical use examined prostate cancer diagnoses on >122,000 slides and 9200 cases over 3 years and had an overall AI Impact â„¢ factor of 1.8%. The potential of AI to be a powerful, reliable, and effective diagnostic tool for pathologists is highlighted, while the AI Impactâ„¢ in a real-world setting demonstrates the ability of AI to standardize prostate cancer diagnosis at a high level of performance across pathologists.

"Ibex Medical Analytics (Ibex)...announced the publication of a clinical study evaluating Ibex's Galen platform, published in the peer-reviewed journal Pathology, which demonstrated excellent outcomes in detecting cancer and other pathologies in prostate and breast biopsies.... During the study, Galen Prostate demonstrated high accuracy in detecting prostate adenocarcinoma with an Area Under the Curve (AUC) of 0.988. The AI algorithm was also highly accurate in cancer grading, specifically differentiating between low and medium/high-grade Gleason scores with an AUC of 0.994, as well as in identifying perineural invasion. In several cases, Galen Prostate's AI algorithm accurately identified higher Gleason scores than previously evaluated by a pathologist and unveiled previously undetected cancer, showcasing its potential to enhance diagnostic accuracy and reduce inter-observer variability."

Although further improvements are required to accurately differentiate rare cancer subtypes, these findings highlight the potential of these algorithms to enhance the precision and efficiency of prostate and breast cancer diagnosis in Japan. Furthermore, this validation paves the way for broader adoption of these algorithms as decision support tools within the Asian population.

P=N/A; Trial completion date: Mar 2023 --> Dec 2024 | Trial primary completion date: Sep 2022 --> Jul 2024

"These studies, highlighting the value of Ibex's AI-powered cancer diagnostics...A study conducted at Brigham and Women's Hospital and Champalimaud Foundation evaluated Galen Breast's performance in identifying microinvasive carcinoma of the breast in a challenging patient cohort. Microinvasive carcinoma is defined as the focus of invasive breast cancer no larger than 1mm, in which accurate detection has important implications for patient management. The results indicate that Galen Breast's AI algorithm is highly accurate in detecting microinvasive lesions and has the potential to improve consistency in diagnosis and support more efficient workflows in pathology laboratories...The study found the AI-powered solution was highly accurate in identifying and grading cancer in a live clinical setting, with NPV and PPV of 0.99....Ibex will be showcasing these findings at the USCAP Annual Meeting taking place in Baltimore, Maryland, between March 23 to 28, at booth number 755."